The epithelioma treatment market size has grown strongly in recent years. It will grow from $5.19 billion in 2025 to $5.69 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing incidence of epithelial tumors, expansion of oncology treatment facilities, advancements in surgical oncology, adoption of radiation therapy technologies, growing clinical research in cancer treatment.
The epithelioma treatment market size is expected to see strong growth in the next few years. It will grow to $8.16 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, rising investments in oncology drug development, expansion of advanced diagnostic imaging, growing adoption of combination treatment regimens, increasing focus on improving patient survival outcomes. Major trends in the forecast period include increasing adoption of targeted cancer therapies, rising use of combination treatment approaches, growing integration of precision oncology diagnostics, expansion of minimally invasive surgical techniques, enhanced focus on early tumor detection.
The increasing incidence of skin cancers is expected to drive the growth of the epithelioma treatment market in the coming years. Skin cancer is characterized by the uncontrolled proliferation of abnormal skin cells caused by unrepaired DNA damage that leads to genetic mutations. Greater exposure to ultraviolet radiation from sunlight and tanning devices, along with environmental factors such as ozone layer depletion, is a key contributor to the rising number of skin cancer cases. Epithelioma treatments work by targeting and eliminating malignant epithelial cells, thereby addressing the underlying cause of the disease. For example, in January 2024, according to the American Cancer Society, a US-based non-profit organization, approximately 100,640 new melanoma cases were projected in the United States in 2024, including about 59,170 cases in men and 41,470 cases in women. Therefore, the growing prevalence of skin cancers is contributing to the expansion of the epithelioma treatment market.
Leading companies operating in the epithelioma treatment market are concentrating on the development of advanced and innovative therapies, such as companion diagnostics, to improve treatment accuracy, enhance patient outcomes, and support personalized medicine approaches. Companion diagnostics are tests designed to identify patients who are most likely to benefit from a specific therapy, thereby improving treatment safety and effectiveness. For instance, in November 2024, Roche Holdings AG, a Switzerland-based pharmaceutical company, received approval from the US Food and Drug Administration for an expanded indication of its PATHWAY anti-HER2/neu (4B5) rabbit monoclonal primary antibody test. This approval enables the test to identify patients with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer who may be eligible for treatment with Ziihera (zanidatamab-hrii). Through this initiative, Roche aims to advance personalized healthcare by offering a dependable diagnostic solution to guide targeted treatment decisions.
In March 2025, Sun Pharmaceutical Industries, an India-based pharmaceutical company, acquired Checkpoint Therapeutics, Inc. for US$355 million. This acquisition is intended to strengthen Sun Pharma’s onco-dermatology portfolio by incorporating Checkpoint’s FDA-approved immunotherapy, UNLOXCYT (cosibelimab ipdl), which is used to treat advanced cutaneous squamous cell carcinoma. Checkpoint Therapeutics, Inc. is a US-based company specializing in immunotherapy and targeted oncology treatments, including therapies for advanced epithelioma.
Major companies operating in the epithelioma treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Verrica Pharmaceuticals Inc., Sirnaomics Inc., MediWound Ltd, Philogen SpA, PellePharm Inc., Kintor Pharmaceutical Limited, DermBiont, Transgene SA, AiViva BioPharma Inc.
North America was the largest region in the epithelioma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelioma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epithelioma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the epithelioma treatment market by increasing costs of imported oncology drugs, radiation equipment components, surgical instruments, diagnostic devices, and advanced pharmaceutical ingredients. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported treatment technologies, while Asia-Pacific faces higher costs in drug manufacturing and export. These tariffs are contributing to higher treatment expenses and procurement challenges. However, they are also supporting domestic pharmaceutical production, regional oncology research initiatives, and local manufacturing of medical treatment equipment.
The epithelioma treatment market research report is one of a series of new reports that provides epithelioma treatment market statistics, including epithelioma treatment industry global market size, regional shares, competitors with a epithelioma treatment market share, detailed epithelioma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the epithelioma treatment industry. This epithelioma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Epithelioma treatment refers to medical interventions aimed at managing epithelioma, a tumor that develops from epithelial cells covering various surfaces and organs of the body. Treatment options include tumor removal through surgery, radiation therapy to target malignant cells, and chemotherapy for more advanced or widespread cases. The choice of treatment depends on the tumor's type, stage, and location, as well as the patient’s overall health and preferences.
The primary types of epithelioma requiring treatment are basal cell epithelioma, squamous cell epithelioma, and malignant epithelioma. Basal cell epithelioma is a slow-growing tumor of the skin that originates from the basal cells in the epidermis. Treatment methods for this condition include drug therapies, surgery, radiation therapy, photodynamic therapy, and combination treatments. These therapies are distributed through hospital pharmacies, retail pharmacies, e-commerce platforms, and other channels. The treatments are most commonly used in hospitals, specialty clinics, ambulatory surgical centers, and academic or research institutions.
The epithelioma treatment market consists of revenues earned by entities providing services such as radiation therapy, chemotherapy, and targeted therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The epithelioma treatment market also includes sales of pharmaceuticals, immunotherapy drugs, and advanced treatment modalities designed to improve patient outcomes and reduce the risk of recurrence or metastasis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The epithelioma treatment market size is expected to see strong growth in the next few years. It will grow to $8.16 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, rising investments in oncology drug development, expansion of advanced diagnostic imaging, growing adoption of combination treatment regimens, increasing focus on improving patient survival outcomes. Major trends in the forecast period include increasing adoption of targeted cancer therapies, rising use of combination treatment approaches, growing integration of precision oncology diagnostics, expansion of minimally invasive surgical techniques, enhanced focus on early tumor detection.
The increasing incidence of skin cancers is expected to drive the growth of the epithelioma treatment market in the coming years. Skin cancer is characterized by the uncontrolled proliferation of abnormal skin cells caused by unrepaired DNA damage that leads to genetic mutations. Greater exposure to ultraviolet radiation from sunlight and tanning devices, along with environmental factors such as ozone layer depletion, is a key contributor to the rising number of skin cancer cases. Epithelioma treatments work by targeting and eliminating malignant epithelial cells, thereby addressing the underlying cause of the disease. For example, in January 2024, according to the American Cancer Society, a US-based non-profit organization, approximately 100,640 new melanoma cases were projected in the United States in 2024, including about 59,170 cases in men and 41,470 cases in women. Therefore, the growing prevalence of skin cancers is contributing to the expansion of the epithelioma treatment market.
Leading companies operating in the epithelioma treatment market are concentrating on the development of advanced and innovative therapies, such as companion diagnostics, to improve treatment accuracy, enhance patient outcomes, and support personalized medicine approaches. Companion diagnostics are tests designed to identify patients who are most likely to benefit from a specific therapy, thereby improving treatment safety and effectiveness. For instance, in November 2024, Roche Holdings AG, a Switzerland-based pharmaceutical company, received approval from the US Food and Drug Administration for an expanded indication of its PATHWAY anti-HER2/neu (4B5) rabbit monoclonal primary antibody test. This approval enables the test to identify patients with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer who may be eligible for treatment with Ziihera (zanidatamab-hrii). Through this initiative, Roche aims to advance personalized healthcare by offering a dependable diagnostic solution to guide targeted treatment decisions.
In March 2025, Sun Pharmaceutical Industries, an India-based pharmaceutical company, acquired Checkpoint Therapeutics, Inc. for US$355 million. This acquisition is intended to strengthen Sun Pharma’s onco-dermatology portfolio by incorporating Checkpoint’s FDA-approved immunotherapy, UNLOXCYT (cosibelimab ipdl), which is used to treat advanced cutaneous squamous cell carcinoma. Checkpoint Therapeutics, Inc. is a US-based company specializing in immunotherapy and targeted oncology treatments, including therapies for advanced epithelioma.
Major companies operating in the epithelioma treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Verrica Pharmaceuticals Inc., Sirnaomics Inc., MediWound Ltd, Philogen SpA, PellePharm Inc., Kintor Pharmaceutical Limited, DermBiont, Transgene SA, AiViva BioPharma Inc.
North America was the largest region in the epithelioma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelioma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epithelioma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the epithelioma treatment market by increasing costs of imported oncology drugs, radiation equipment components, surgical instruments, diagnostic devices, and advanced pharmaceutical ingredients. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported treatment technologies, while Asia-Pacific faces higher costs in drug manufacturing and export. These tariffs are contributing to higher treatment expenses and procurement challenges. However, they are also supporting domestic pharmaceutical production, regional oncology research initiatives, and local manufacturing of medical treatment equipment.
The epithelioma treatment market research report is one of a series of new reports that provides epithelioma treatment market statistics, including epithelioma treatment industry global market size, regional shares, competitors with a epithelioma treatment market share, detailed epithelioma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the epithelioma treatment industry. This epithelioma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Epithelioma treatment refers to medical interventions aimed at managing epithelioma, a tumor that develops from epithelial cells covering various surfaces and organs of the body. Treatment options include tumor removal through surgery, radiation therapy to target malignant cells, and chemotherapy for more advanced or widespread cases. The choice of treatment depends on the tumor's type, stage, and location, as well as the patient’s overall health and preferences.
The primary types of epithelioma requiring treatment are basal cell epithelioma, squamous cell epithelioma, and malignant epithelioma. Basal cell epithelioma is a slow-growing tumor of the skin that originates from the basal cells in the epidermis. Treatment methods for this condition include drug therapies, surgery, radiation therapy, photodynamic therapy, and combination treatments. These therapies are distributed through hospital pharmacies, retail pharmacies, e-commerce platforms, and other channels. The treatments are most commonly used in hospitals, specialty clinics, ambulatory surgical centers, and academic or research institutions.
The epithelioma treatment market consists of revenues earned by entities providing services such as radiation therapy, chemotherapy, and targeted therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The epithelioma treatment market also includes sales of pharmaceuticals, immunotherapy drugs, and advanced treatment modalities designed to improve patient outcomes and reduce the risk of recurrence or metastasis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Epithelioma Treatment Market Characteristics
3. Epithelioma Treatment Market Supply Chain Analysis
4. Global Epithelioma Treatment Market Trends and Strategies
5. Epithelioma Treatment Market Analysis of End Use Industries
7. Global Epithelioma Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Epithelioma Treatment Total Addressable Market (TAM) Analysis for the Market
9. Epithelioma Treatment Market Segmentation
10. Epithelioma Treatment Market Regional and Country Analysis
11. Asia-Pacific Epithelioma Treatment Market
12. China Epithelioma Treatment Market
13. India Epithelioma Treatment Market
14. Japan Epithelioma Treatment Market
15. Australia Epithelioma Treatment Market
16. Indonesia Epithelioma Treatment Market
17. South Korea Epithelioma Treatment Market
18. Taiwan Epithelioma Treatment Market
19. South East Asia Epithelioma Treatment Market
20. Western Europe Epithelioma Treatment Market
21. UK Epithelioma Treatment Market
22. Germany Epithelioma Treatment Market
23. France Epithelioma Treatment Market
24. Italy Epithelioma Treatment Market
25. Spain Epithelioma Treatment Market
26. Eastern Europe Epithelioma Treatment Market
27. Russia Epithelioma Treatment Market
28. North America Epithelioma Treatment Market
29. USA Epithelioma Treatment Market
30. Canada Epithelioma Treatment Market
31. South America Epithelioma Treatment Market
32. Brazil Epithelioma Treatment Market
33. Middle East Epithelioma Treatment Market
34. Africa Epithelioma Treatment Market
36. Epithelioma Treatment Market Competitive Landscape and Company Profiles
37. Epithelioma Treatment Market Other Major and Innovative Companies
40. Epithelioma Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Epithelioma Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses epithelioma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for epithelioma treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The epithelioma treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Disease Type: Basal Cell Epithelioma; Squamous Cell Epithelioma; Malignant Epithelioma2) By Treatment Type: Drug Class; Surgical Treatments; Radiation Therapy; Photodynamic Therapy; Combination Therapies
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; E-Commerce; Other Distribution Channels
4) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Research And Academic Institutes
Subsegments:
1) By Basal Cell Epithelioma: Superficial Basal Cell Epithelioma; Nodular Basal Cell Epithelioma; Infiltrative Basal Cell Epithelioma; Morpheaform (Sclerosing) Basal Cell Epithelioma; Pigmented Basal Cell Epithelioma2) By Squamous Cell Epithelioma: Cutaneous Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Pulmonary Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma
3) By Malignant Epithelioma: Epithelioid Sarcoma; Clear Cell Sarcoma; Spindle Cell Carcinoma; Adenoid Cystic Carcinoma; Mucoepidermoid Carcinoma
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Sanofi; Bristol-Myers Squibb Company; Novartis AG; Eli Lilly and Company; Amgen Inc.; Regeneron Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; Zhejiang Hisun Pharmaceutical Co. Ltd.; Verrica Pharmaceuticals Inc.; Sirnaomics Inc.; MediWound Ltd; Philogen SpA; PellePharm Inc.; Kintor Pharmaceutical Limited; DermBiont; Transgene SA; AiViva BioPharma Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Epithelioma Treatment market report include:- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Sanofi
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Verrica Pharmaceuticals Inc.
- Sirnaomics Inc.
- MediWound Ltd
- Philogen SpA
- PellePharm Inc.
- Kintor Pharmaceutical Limited
- DermBiont
- Transgene SA
- AiViva BioPharma Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.69 Billion |
| Forecasted Market Value ( USD | $ 8.16 Billion |
| Compound Annual Growth Rate | 9.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
